NICE Recommends Lucentis® (Ranibizumab) For Some Patients With Visual Impairment Due To Diabetic Macular Oedema (VI-DMO) In Draft Guidance

The National Institute for Health and Clinical Excellence (NICE) has today issued positive draft guidance on the use of ranibizumab for the treatment of VI-DMO, an eye condition which can occur in people with diabetes that causes blurred vision, severe vision loss and sometimes blindness[1],[2],[3]. This means that some patients (those with a retinal thickness of 400 micrometres or more), could soon benefit from a treatment which can potentially restore vision, prevent vision loss and sustain visual improvement[4]...
Read more »